李洁喜;饶媛;史荣华;
LI Jiexi;RAO Yuan;SHI Ronghua;Department of Pharmacy,Chashan Hospital of Dongguan;Department of Internal Medicine,Chashan Hospital of Dongguan;

• 1:东莞市茶山医院药剂科
• 2:东莞市茶山医院内科

摘要(Abstract)：

目的 分析HLA-B^*5801和CYP2C9*5801和CYP2C9^*3基因检测与降尿酸药物应用之间的合理性。方法 通过回顾性研究方法，选取2019年6月～2021年5月在某院行HLA-B*3基因检测与降尿酸药物应用之间的合理性。方法 通过回顾性研究方法，选取2019年6月～2021年5月在某院行HLA-B^*5801和CYP2C9*5801和CYP2C9^*3基因检测的高尿酸血症患者95例，分析HLA-B*3基因检测的高尿酸血症患者95例，分析HLA-B^*5801和CYP2C9*5801和CYP2C9^*3基因检测结果与降尿酸药物应用之间的情况，以及药物不良反应的相关性。结果 75例患者行HLA-B*3基因检测结果与降尿酸药物应用之间的情况，以及药物不良反应的相关性。结果 75例患者行HLA-B^*5801基因检测的阳性率16.0%;82例患者行CYP2C9*5801基因检测的阳性率16.0%;82例患者行CYP2C9^*3基因检测，其中*3基因检测，其中^*1/*1/^*1、*1、^*1/*1/^*3、*3、^*3/*3/^*3基因型分别有78,3,1例。别嘌醇和苯溴马隆用药不合理率分别为5.7%(2/35)和73.7%(42/57)。其次，HLA-B*3基因型分别有78,3,1例。别嘌醇和苯溴马隆用药不合理率分别为5.7%(2/35)和73.7%(42/57)。其次，HLA-B^*5801和CYP2C9*5801和CYP2C9^*3基因检测不合理率分别为25.3%和2.4%。别嘌醇和苯溴马隆出现的药物不良反应分别为17.1%和19.3%。结论 在基层医院，尚存在降尿酸药物和相关基因检测的不合理性，应予重视并个体化用药，保证降尿酸治疗的有效和安全，以及减少不必要的检测。
OBJECTIVE To analyze the rationality of HLA-B*3基因检测不合理率分别为25.3%和2.4%。别嘌醇和苯溴马隆出现的药物不良反应分别为17.1%和19.3%。结论 在基层医院，尚存在降尿酸药物和相关基因检测的不合理性，应予重视并个体化用药，保证降尿酸治疗的有效和安全，以及减少不必要的检测。
OBJECTIVE To analyze the rationality of HLA-B^*5801 and CYP2C9*5801 and CYP2C9^*3 gene tests on the application of antihyperuricemic drugs in patients with hyperuricemia.METHODS A retrospective study was conducted to analyze the relevant antihyperuricemic drugs and genotypes of 95 patients with hyperuricemia who received HLA-B*3 gene tests on the application of antihyperuricemic drugs in patients with hyperuricemia.METHODS A retrospective study was conducted to analyze the relevant antihyperuricemic drugs and genotypes of 95 patients with hyperuricemia who received HLA-B^*5801 and CYP2C9*5801 and CYP2C9^*3 gene tests in Dongguan Chashan Hospital from June 2019 to May 2021,as well as adverse drug reactions.RESULTS The positive rate of HLA-B*3 gene tests in Dongguan Chashan Hospital from June 2019 to May 2021,as well as adverse drug reactions.RESULTS The positive rate of HLA-B^*5801 gene detection in 75 patients was 16.0%;78,3 and 1 patients with CYP2C9*5801 gene detection in 75 patients was 16.0%;78,3 and 1 patients with CYP2C9^*3 genotypes *3 genotypes ^*1/*1/^*1, *1, ^*1/*1/^*3 and *3 and ^*3/*3/^*3 genotypes were found in 82 patients,respectively.The percentages of antihyperuricemic drugs with irrational rate of allopurinol and benzbromarone were5.7%(2/35) and 73.7%(42/57),respectively-The unreasonable rates of HLA-B*3 genotypes were found in 82 patients,respectively.The percentages of antihyperuricemic drugs with irrational rate of allopurinol and benzbromarone were5.7%(2/35) and 73.7%(42/57),respectively-The unreasonable rates of HLA-B^*5801 and CYP2C9*5801 and CYP2C9^*3 gene detection were 25.3%and 2.4%,respectively.The adverse drug reactions of allopurinol and benzbromarone were 17.1% and 19.3%,respectively.CONCLUSION In primary hospitals,there are still unreasonable application of antihyperuricemic drugs and related gene tests,which should be taken seriously.And the individual medication guidance should be pay attention to ensure the effectiveness and safety of antihyperuricemic drugs treatment and reduce unnecessary tests.

关键词(KeyWords)： 高尿酸血症;基因检测;别嘌醇;苯溴马隆;药物不良反应
hyperuricemia;gene tests;allopurinol;benzbromarone;adverse drug reactions

Abstract:

Keywords:

基金项目(Foundation): 东莞市社会发展科技项目（20211800902902）

作者(Authors): 李洁喜;饶媛;史荣华;
LI Jiexi;RAO Yuan;SHI Ronghua;Department of Pharmacy,Chashan Hospital of Dongguan;Department of Internal Medicine,Chashan Hospital of Dongguan;

参考文献(References)：

• [1]林淑芃.《中国高尿酸血症与痛风诊疗指南(2019)》解读[J].临床内科杂志,2020,37(6):460-462.
• [2]Kuo C F, Grainge M J,ZHANG W,et al.Global epidemiology of gout:prevalence,incidence and risk factors[J].Nature reviews Rheumatology,2015,11(11):649-662.
• [3]Liu R,Han C,Wu D,et al.Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014:A Systematic Review and Meta-Analysis[J].BioMed Research International,2015,15(3):1-12.
• [4]刘威,黎颖然,张文渊,等.中国汉族人群HLA-B*58:01等位基因与别嘌醇引起严重皮肤不良反应关联性的Meta分析[J].今日药学,2019,29(3):177-181.
• [5]周启蒙,赵晓悦,梁宇,等.治疗高尿酸血症相关药物研究新进展[J].中国新药杂志,2021,30(10):929-936.
• [6]Cheng L,Xiong Y,Qin C Z, et al.HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients:a multicentre retrospective case-control clinical study[J].The British Journal of Dermatology, 2015,173(2):555-558.
• [7]Wu R,Cheng Y J,Zhu L L,et al.Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions:evidence from 21 pharmacogenetic studies[J].Oncotarget,2016,4(49):81870-81879.
• [8]Zhang M Y,Niu J Q,Wen X Y,et al.Liver failure associated with benzbromarone:A case report and review of the literature[J].World Journal of Clinical Cases,2019,7(13):1717-1725.
• [9]中华医学会内分泌学分会.中国高尿酸血症与痛风诊疗指南(2019)[J].中华内分泌代谢杂志,2020,36(1):1-13.
• [10]张迪,陈思颖,杨志华,等.慢性肾脏病合并高尿酸血症患者降尿酸药物应用和HLA-B*5801等位基因检测合理性分析[J].药物不良反应杂志,2019,21(1):15-19.
• [11]林令华,孙守兵.CYP2C9基因多态性对苯溴马隆药动学的影响[J].中国新药与临床杂志,2011,30(10):759-762.
• [12]张卫忠,施春花,王友莲.痛风及高尿酸血症患者HLA-B*5801基因携带情况及其与别嘌醇过敏反应间的相关性研究[J].江西医药,2020,55(10):1385-1388.
• [13]Tassaneeyakul W,Jantararoungtong T,Chen P,et al.Strong association between HLA-B*5801 and allop urinol-induced StevensJohnson syndrome and toxic epidermal necrolysis in a Thai population[J].Pharmacogenetics and genomics,2009, 19(9):704-9.
• [14]Yu K H.Yu C Y,Fang Y F.Diagnostic utility of HLA-B*5801screening in severe allopurinol hypersensitivity syndrome:an updated systematic review and meta-analysis[J].International Journal of Rheumatic Diseases,2017,20(9):1057-1071.
• [15]Uchida S,Shimada K,Misaka S,et al.Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9genotypes[J].Drug Metabolism and Pharmacokinetics,2010,25(6):605-610.
• [16]黄晓晖,周国华.精准医学时代下临床药学监护模式新进展[J].医学研究生学报,2019,32(5):455-461.
• [17]徐航,回翔,朱怀军,等.药物基因组学在临床药物治疗中的应用[J].药学与临床研究,2019,27(1):46-51.